Aquestive Therapeutics (AQST) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aquestive Therapeutics (AQST) has outperformed Evotec (EVO) over the past year, losing 22.6% versus a loss of 58.9%. Over five years, AQST leads with a +19.4% price change compared with -92.9% for EVO. Aquestive Therapeutics is the larger company by market cap ($587.4 million vs $550.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | EVO |
|---|---|---|
| Share price | $4.68 | $1.55 |
| Market cap | $587.39M | $550.85M |
| 1-day change | +1.30% | -3.73% |
| YTD return | -28.48% | -47.73% |
| 1-year return | -22.61% | -58.93% |
| 5-year return | +19.38% | -92.87% |
| EPS (TTM) | $-0.66 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $4.27 |
| 52-week low | $2.93 | $1.50 |
| Distance from 52-week high | -38.01% | -63.70% |
| Analyst consensus | none | none |
| Avg. price target upside | +99.36% | +168.39% |
| Average volume | 2.66M | 103.98K |
| Shares outstanding | 125.51M | 355.39M |
| Employees | 147 | 4,461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AQST has outperformed EVO by 36.3 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
AQST vs EVO FAQ
Which is bigger, Aquestive Therapeutics or Evotec?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $587.39M compared with $550.85M for Evotec (EVO).
Which stock has performed better over the past year, AQST or EVO?
AQST returned -22.61% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.